Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 12/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | YES1 | P07947 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.43 |
| ▸ | CD63 | P08962 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217622 | 0.93 | MAPKAPK5 (0.64) | MAPKAPK5CYP1A1CYP1A2CYP1B1MAPT | |
| SCHEMBL1476709 | 0.87 | MAPKAPK5 (0.58) | MAPKAPK5CYP1A1CYP1A2CYP1B1SYK | |
| SCHEMBL3801156 | 0.85 | MAPKAPK5 (0.58) | MAPKAPK5CYP1A1CYP1A2CYP1B1SYK | |
| SCHEMBL1477651 | 0.85 | MAPKAPK5 (0.57) | MAPKAPK5 | |
| SCHEMBL2218922 | 0.84 | MAPKAPK5 (0.71) | MAPKAPK5NPC1POLBMAPTRAB9A | |
| SCHEMBL3800071 | 0.82 | MAPKAPK5 (0.56) | MAPKAPK5ABL1NTRK1YES1KDR | |
| SCHEMBL1476354 | 0.81 | MAPKAPK5 (0.70) | MAPKAPK5NPC1POLBMAPTRAB9A | |
| SCHEMBL1476125 | 0.79 | MAPKAPK5 (0.75) | MAPKAPK5SYK | |
| SCHEMBL1475590 | 0.78 | MAPKAPK5 (0.61) | MAPKAPK5NPC1POLBMAPTRAB9A | |
| SCHEMBL1475901 | 0.78 | MAPKAPK5 (1.00) | MAPKAPK5NPC1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | MAPKAPK5 18/4885CYP1A1 1274/4885CYP1A2 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.